Cargando…

BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells

Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation often obtain de novo resistance or develop secondary resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs), which restricts the clinical benefit for the patients. The activation of phosphatidylinosi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Yaya, Xiao, Zhenzhen, Lei, Chenjing, Ma, Changju, Ding, Lina, Tang, Qing, He, Yihan, Chen, Yadong, Chang, Xuesong, Zhu, Yanjuan, Zhang, Haibo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408073/ https://www.ncbi.nlm.nih.gov/pubmed/37553597 http://dx.doi.org/10.1186/s12885-023-11243-0

Ejemplares similares

Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs
por: Boyd, David C., et al.
Publicado: (2023)

PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy
por: Chuang, Fu-Cheng, et al.
Publicado: (2021)

Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells
por: Piazzi, Manuela, et al.
Publicado: (2022)

Efficacy of Providing the PI3K p110α Inhibitor BYL719 (Alpelisib) to Middle-Aged Mice in Their Diet
por: Hedges, Christopher P., et al.
Publicado: (2021)

Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors
por: Ando, Yuichi, et al.
Publicado: (2019)

The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models
por: Nölting, Svenja, et al.
Publicado: (2017)

HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma
por: Meister, Kara S., et al.
Publicado: (2019)

Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant
por: Jacquemetton, Julien, et al.
Publicado: (2021)

Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer
por: Yuan, Yuan, et al.
Publicado: (2019)

MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway
por: Jiang, Jingjin, et al.
Publicado: (2016)

Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
por: Watanabe, Satoshi, et al.
Publicado: (2014)

HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer
por: Han, Shuyan, et al.
Publicado: (2023)

Sensitization of Non-Small Cell Lung Cancer Cells to Gefitinib and Reversal of Epithelial–Mesenchymal Transition by Aloe-Emodin Via PI3K/Akt/TWIS1 Signal Blockage
por: Peng, Minghui, et al.
Publicado: (2022)

Impact of Weissella cibaria BYL4.2 and its supernatants on Penicillium chrysogenum metabolism
por: Yao, Di, et al.
Publicado: (2022)

Gefitinib induces lung cancer cell autophagy and apoptosis via blockade of the PI3K/AKT/mTOR pathway
por: ZHAO, ZHONG-QUAN, et al.
Publicado: (2016)

Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer
por: Zhu, Xinhai, et al.
Publicado: (2016)

Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis
por: Deng, Qin-fang, et al.
Publicado: (2020)

Poster Sessions 555 - 719
Publicado: (2003)

SFI Enhances Therapeutic Efficiency of Gefitinib: An Insight into Reversal of Resistance to Targeted Therapy in Non-small Cell Lung Cancer Cells
por: Pan, Zhenzhen, et al.
Publicado: (2020)

NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation
por: Sun, Zhihua, et al.
Publicado: (2015)

Gefitinib-coated balloon inhibits the excessive hyperplasia of intima after vascular injuries through PI3K/AKT pathway
por: Tang, Fen, et al.
Publicado: (2019)

LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signaling pathway in lung adenocarcinoma
por: Ding, Jianghua, et al.
Publicado: (2022)

Tanshinone IIA Reverses Gefitinib-Resistance In Human Non-Small-Cell Lung Cancer Via Regulation Of VEGFR/Akt Pathway
por: Wang, Rui, et al.
Publicado: (2019)

LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC
por: Liu, Xinyin, et al.
Publicado: (2019)

Linc01014 regulates gefitinib resistance in oesophagus cancer via EGFR‐PI3K‐AKT‐mTOR signalling pathway
por: Fu, Xiao, et al.
Publicado: (2019)

M2 macrophages reduce the effect of gefitinib by activating AKT/mTOR in gefitinib‐resistant cell lines HCC827/GR
por: Xiao, Fengqi, et al.
Publicado: (2020)

A Clinical Nomogram for Predicting Cancer-Specific Survival in Pulmonary Large-Cell Neuroendocrine Carcinoma Patients: A Population-Based Study
por: Ma, Haochuan, et al.
Publicado: (2021)

RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K/AKT pathway in lung adenocarcinoma
por: Gao, Fangyan, et al.
Publicado: (2021)

Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT
por: Yang, J, et al.
Publicado: (2015)

Yang-Yin-Jie-Du decoction overcomes gefitinib resistance in non-small cell lung cancer via down-regulation of the PI3K/Akt signalling pathway
por: Chen, Shu-yi, et al.
Publicado: (2021)

Correction to Lancet Oncol 2017; 18: 719–31
Publicado: (2017)

SUN-719 The Impact of FOXA3 on Testicular Steroidogenesis
por: Kim, Hansle, et al.
Publicado: (2020)

Verteporfin reverses progestin resistance through YAP/TAZ-PI3K-Akt pathway in endometrial carcinoma
por: Wei, Lina, et al.
Publicado: (2023)

Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway
por: Wang, Bing, et al.
Publicado: (2017)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro
por: Zhuang, Hong-Qing, et al.
Publicado: (2009)

Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells
por: Wu, Kai, et al.
Publicado: (2013)

Cryptotanshinone Inhibites Bladder Cancer Cell Proliferation and Promotes Apoptosis via the PTEN/PI3K/AKT Pathway
por: Liu, Yadong, et al.
Publicado: (2020)

719. The Respiratory Pathogen Panel and Antibiotic Utilization in the Emergency Department
por: Taupin, Daniel, et al.
Publicado: (2018)

MON-719 The Cellular and Molecular Landscape of Hypothalamic Patterning and Differentiation
por: Kim, Thomas
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sro3dst3gu70balntkbnl8q0oj